NCT00954590View on ClinicalTrials.gov

A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

August 31, 2010

Conditions
Moderate to Severe Alzheimer
Interventions
DRUG

Dimebon (latrepirdine)

20 mg orally three times daily

DRUG

Placebo

Placebo orally three times daily

Trial Locations (2)

Unknown

Santiago

Glasgow

Sponsors

Lead Sponsor

Medivation, Inc.

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Medivation, Inc.

INDUSTRY